Stock Futures Subdued as Markets Await Fed Meeting Minutes
Stock futures are subdued on the penultimate trading day of the year as markets contend with light year-end volumes and a pullback in heavyweight tech and AI names that stalled last week's strong rally. Investors are also awaiting the release of the Federal Reserve's December meeting minutes and digesting recent economic signals that have fueled debate over the pace of future rate cuts.Precious metals have rebounded after a brief sell-off, with gold futures edging higher following Monday's decline, reflecting ongoing demand for safe-haven assets as the year closes. With trading volumes expected to remain light ahead of New Year's Eve and markets closed Thursday for the holiday, price action remains driven more by positioning and positioning adjustments than by fresh catalysts.In pre-market trading, S&P 500 futures fell 0.08%, Nasdaq futures fell 0.16% and Dow futures fell 0.03%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Ekso Bionicsand Applied Digitalup 46% and 2%, respectively, after the companies entered into a non-binding term sheet for a proposed business combination of Applied Digital's cloud computing business with EksoOn24up 36% after entering into a definitive agreement to be acquired by Cvent for $8.10 per share in cashVolatoup 7% after announcing that it has elected to pause its at-the-market equity offering program through June 30, 2026Boeingup 1% after being awarded a ceiling $8.58B hybrid cost-plus-fixed-fee, fixed-price incentive, firm-fixed-price, undefinitized contract action for the F-15 Israel ProgramCemtrexup 37% after reporting FY25 results
Get Free Real-Time Notifications for Any Stock
Analyst Views on EKSO
About EKSO
About the author
Ekso Bionics (EKSO) Completes Private Placement of 5,852 Preferred Shares Raising $5.9 Million
- Private Placement Agreement: Ekso Bionics entered into securities purchase agreements on January 20, 2026, with institutional and accredited investors for a private placement of 5,852 shares of Series B preferred stock and warrants to purchase 360,000 common shares, expecting to raise $5.9 million for working capital and general corporate purposes.
- Preferred Stock Conversion Terms: Each preferred share has a stated value of $1,000 and can be converted into common stock at any time at $8.22 per share, representing a total potential conversion into 710,000 common shares, enhancing investor return potential.
- Warrant Details: The warrants will become exercisable six months after closing at $8.22 per share and will expire five years thereafter, providing an investment opportunity should the stock price rise in the future.
- Market Reaction: Despite the financing announcement, Ekso Bionics' stock price fell by 7.22%, reflecting market caution regarding the company's future prospects, which may impact the effectiveness of the financing.
Ekso Bionics Secures $5.9 Million in Private Placement of 5,852 Shares of Preferred Stock
- Financing Size: On January 20, 2026, Ekso Bionics entered into agreements with institutional investors to sell 5,852 shares of Preferred Stock, expected to raise $5.9 million, enhancing the company's liquidity to support operations.
- Preferred Stock Conversion: Each Preferred Stock has a stated value of $1,000 and a conversion price of $8.22 per share, potentially converting into 711,922 shares of common stock, thereby increasing shareholder equity and market appeal.
- Warrant Terms: The transaction also includes warrants for 355,960 shares of common stock, with an exercise price of $8.22, valid for five years, enhancing potential returns for investors.
- Transaction Timeline: The private placement is expected to close around January 22, 2026, subject to customary closing conditions, ensuring timely access to funds to support the company's strategic development.
